Area of research
Surgery · Cardiology and Cardiovascular Medicine
Research interest
Research focused on Stenosis and Valve replacement, with related work in MitraClip, Percutaneous coronary intervention, Clinical endpoint. Notable publications include 'Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis', 'Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents', and 'Transcatheter Aortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for Surgery'.
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention
1-Year Outcomes From the CLASP IID Randomized Trial for Degenerative Mitral Regurgitation
Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial
1-Year Outcomes of Transcatheter Edge-to-Edge Repair in Anatomically Complex Degenerative Mitral Regurgitation Patients
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
Valve-in-Surgical-Valve With SAPIEN 3 for Transcatheter Aortic Valve Replacement Based on Society of Thoracic Surgeons Predicted Risk of Mortality
Early outcomes from the <scp>CLASP IID</scp> trial roll‐in cohort for prohibitive risk patients with degenerative mitral regurgitation
Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic
The Effect and Relationship of Frailty Indices on Survival After Transcatheter Aortic Valve Replacement
Triage considerations for patients referred for structural heart disease intervention during the <scp>COVID</scp>‐19 pandemic: An ACC/SCAI position statement
Durability and Clinical Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses
Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients
Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents
Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation
2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Transcatheter Aortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for Surgery
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
Effects of Atrial Fibrillation on Treatment of Mitral Regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) Randomized Trial
Clinical outcomes in real‐world patients with acute myocardial infarction receiving XIENCE V<sup>®</sup> everolimus‐eluting stents